Two new high-performance reagents deliver more viable cells, help accelerate cellular and molecular research efforts
PENZBERG, Germany--(BUSINESS WIRE)-- Roche (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY) announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research. Designed for commonly used and hard-to-transfect cell lines, the X-tremeGENE 9 and X-tremeGENE HP reagents offer high efficiency, reproducibility and cell survival rates, compared to leading transfection reagents, to deliver more viable cells and help accelerate research efforts. Both reagents support a wide variety of cellular and molecular research applications, such as gene expression analysis and protein production.
The two new products build on Roche’s 20 years of experience with transfection reagents. The X-tremeGENE 9 reagent offers efficient performance across a wide variety of commonly used cell lines while Roche’s X-tremeGENE HP reagent is especially well suited for cell lines that are difficult to transfect or not easily transfected with other reagents.
Both reagents combine low cytotoxicity with high efficiency and reproducibility, providing more viable cells with more physiologically relevant results. They also offer easy-to-implement protocols: Researchers simply dilute the reagent, incubate it with plasmid DNA, and pipette it directly onto cells. The simple process enables researchers to spend less time optimizing the reagent and more time advancing their research.
Both reagents function well in the presence or absence of serum and remain stable after repeated vial openings, helping to save researchers time and effort. More information is available at www.x-tremegene.roche.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For life science research only. Not for use in diagnostic procedures.
X-tremeGENE is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
KEYWORDS: United States Europe North America Germany Switzerland
INDUSTRY KEYWORDS: Stem Cells Health Genetics Medical Devices Pharmaceutical Research Science